Novel intravascular tantalum oxide-based contrast agent achieves improved vascular contrast enhancement and conspicuity compared to Iopamidol in an animal multiphase CT protocol.

IF 3.7 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Maurice M Heimer, Yuxin Sun, Sergio Grosu, Clemens C Cyran, Peter J Bonitatibus, Nikki Okwelogu, Brian C Bales, Dan E Meyer, Benjamin M Yeh
{"title":"Novel intravascular tantalum oxide-based contrast agent achieves improved vascular contrast enhancement and conspicuity compared to Iopamidol in an animal multiphase CT protocol.","authors":"Maurice M Heimer, Yuxin Sun, Sergio Grosu, Clemens C Cyran, Peter J Bonitatibus, Nikki Okwelogu, Brian C Bales, Dan E Meyer, Benjamin M Yeh","doi":"10.1186/s41747-024-00509-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To assess thoracic vascular computed tomography (CT) contrast enhancement of a novel intravenous tantalum oxide nanoparticle contrast agent (carboxybetaine zwitterionic tantalum oxide, TaCZ) compared to a conventional iodinated contrast agent (Iopamidol) in a rabbit multiphase protocol.</p><p><strong>Methods: </strong>Five rabbits were scanned inside a human-torso-sized encasement on a clinical CT system at various scan delays after intravenous injection of 540 mg element (Ta or I) per kg of bodyweight of TaCZ or Iopamidol. Net contrast enhancement of various arteries and veins, as well as image noise, were measured. Randomized scan series were reviewed by three independent readers on a clinical workstation and assessed for vascular conspicuity and image artifacts on 5-point Likert scales.</p><p><strong>Results: </strong>Overall, net vascular contrast enhancement achieved with TaCZ was superior to Iopamidol (p ≤ 0.036 with the exception of the inferior vena cava at 6 s (p = 0.131). Vascular contrast enhancement achieved with TaCZ at delays of 6 s, 40 s, and 75 s was superior to optimum achieved Iopamidol contrast enhancement at 6 s (p ≤ 0.036. Vascular conspicuity was higher for TaCZ in 269 of 300 (89.7%) arterial and 269 of 300 (89.7%) venous vessel assessments, respectively (p ≤ 0.005), with substantial inter-reader reliability (κ = 0.61; p < 0.001) and strong positive monotonic correlation between conspicuity scores and contrast enhancement measurements (ρ = 0.828; p < 0.001).</p><p><strong>Conclusion: </strong>TaCZ provides absolute and relative contrast advantages compared to Iopamidol for improved visualization of thoracic arteries and veins in a multiphase CT protocol.</p><p><strong>Relevance statement: </strong>The tantalum-oxide nanoparticle is an experimental intravenous CT contrast agent with superior cardiovascular and venous contrast capacity per injected elemental mass in an animal model, providing improved maximum contrast enhancement and prolonged contrast conspicuity. Further translational research on promising high-Z and nanoparticle contrast agents is warranted.</p><p><strong>Key points: </strong>There have been no major advancements in intravenous CT contrast agents over decades. Iodinated CT contrast agents require optimal timing for angiography and phlebography. Tantalum-oxide demonstrated increased CT attenuation per elemental mass compared to Iopamidol. Nanoparticle contrast agent design facilitates prolonged vascular conspicuity.</p>","PeriodicalId":36926,"journal":{"name":"European Radiology Experimental","volume":"8 1","pages":"108"},"PeriodicalIF":3.7000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452362/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology Experimental","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41747-024-00509-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To assess thoracic vascular computed tomography (CT) contrast enhancement of a novel intravenous tantalum oxide nanoparticle contrast agent (carboxybetaine zwitterionic tantalum oxide, TaCZ) compared to a conventional iodinated contrast agent (Iopamidol) in a rabbit multiphase protocol.

Methods: Five rabbits were scanned inside a human-torso-sized encasement on a clinical CT system at various scan delays after intravenous injection of 540 mg element (Ta or I) per kg of bodyweight of TaCZ or Iopamidol. Net contrast enhancement of various arteries and veins, as well as image noise, were measured. Randomized scan series were reviewed by three independent readers on a clinical workstation and assessed for vascular conspicuity and image artifacts on 5-point Likert scales.

Results: Overall, net vascular contrast enhancement achieved with TaCZ was superior to Iopamidol (p ≤ 0.036 with the exception of the inferior vena cava at 6 s (p = 0.131). Vascular contrast enhancement achieved with TaCZ at delays of 6 s, 40 s, and 75 s was superior to optimum achieved Iopamidol contrast enhancement at 6 s (p ≤ 0.036. Vascular conspicuity was higher for TaCZ in 269 of 300 (89.7%) arterial and 269 of 300 (89.7%) venous vessel assessments, respectively (p ≤ 0.005), with substantial inter-reader reliability (κ = 0.61; p < 0.001) and strong positive monotonic correlation between conspicuity scores and contrast enhancement measurements (ρ = 0.828; p < 0.001).

Conclusion: TaCZ provides absolute and relative contrast advantages compared to Iopamidol for improved visualization of thoracic arteries and veins in a multiphase CT protocol.

Relevance statement: The tantalum-oxide nanoparticle is an experimental intravenous CT contrast agent with superior cardiovascular and venous contrast capacity per injected elemental mass in an animal model, providing improved maximum contrast enhancement and prolonged contrast conspicuity. Further translational research on promising high-Z and nanoparticle contrast agents is warranted.

Key points: There have been no major advancements in intravenous CT contrast agents over decades. Iodinated CT contrast agents require optimal timing for angiography and phlebography. Tantalum-oxide demonstrated increased CT attenuation per elemental mass compared to Iopamidol. Nanoparticle contrast agent design facilitates prolonged vascular conspicuity.

在动物多相 CT 方案中,与碘帕米多相比,新型血管内氧化钽造影剂可改善血管造影剂的增强效果和清晰度。
背景:目的:在兔子多相方案中,评估新型氧化钽纳米颗粒造影剂(羧基甜菜碱齐聚物氧化钽,TaCZ)与传统碘化造影剂(碘帕米醇)相比的胸部血管计算机断层扫描(CT)造影剂增强效果:方法:在临床 CT 系统上,向五只兔子静脉注射每公斤体重 540 毫克元素(Ta 或 I)的 TaCZ 或 Iopamidol 后,在不同的扫描延迟时间内对兔子进行人体躯干大小的包裹扫描。对各种动脉和静脉的净对比度增强以及图像噪声进行了测量。随机扫描序列由临床工作站上的三位独立阅读者进行审查,并以 5 分李克特量表对血管清晰度和图像伪影进行评估:总体而言,TaCZ的血管净对比度增强效果优于碘帕米醇(p≤0.036,6秒时下腔静脉除外(p=0.131))。延迟 6 秒、40 秒和 75 秒时,TaCZ 的血管对比度增强效果优于 6 秒时伊奥帕米多的最佳对比度增强效果(p ≤ 0.036)。在 300 次动脉血管评估中,有 269 次(89.7%)和 300 次静脉血管评估中,有 269 次(89.7%)TaCZ 的血管清晰度更高(p ≤ 0.005),阅片者之间的可靠性也很高(κ = 0.61;p 结论:与碘帕米多相比,TaCZ在多相CT方案中改善胸部动脉和静脉显像方面具有绝对和相对对比优势:钽-氧化物纳米粒子是一种实验性静脉 CT 造影剂,在动物模型中单位注射元素质量具有卓越的心血管和静脉造影能力,可提供更好的最大造影增强和延长造影显影时间。有必要对有前景的高 Z 值和纳米粒子造影剂进行进一步的转化研究:要点:几十年来,静脉 CT 造影剂一直没有重大进展。碘化 CT 造影剂需要最佳的血管造影和静脉造影时机。与碘帕米醇相比,氧化钽的单位元素质量 CT 衰减更强。纳米粒子造影剂的设计有利于延长血管的清晰度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Radiology Experimental
European Radiology Experimental Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
6.70
自引率
2.60%
发文量
56
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信